Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.

Literature DB >> 23824358

Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.

I Giordano, M Bogdanow, H Jacobi, K Jahn, M Minnerop, L Schoels, M Synofzik, J Teufel, T Klockgether.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2013 PMID： 23824358 DOI： 10.1007/s00415-013-7029-5

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

10 in total

1. EuroQol--a new facility for the measurement of health-related quality of life.

Authors:
Journal: Health Policy Date: 1990-12 Impact factor: 2.980

Review 2. 4-aminopyridine and cerebellar gait: a retrospective case series.

Authors: Roman Schniepp; Max Wuehr; Maximilian Neuhaeusser; Ann Kathrin Benecke; Christine Adrion; Thomas Brandt; Michael Strupp; Klaus Jahn
Journal: J Neurol Date: 2012-07-04 Impact factor: 4.849

3. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia.

Authors: T Schmitz-Hübsch; P Giunti; D A Stephenson; C Globas; L Baliko; F Saccà; C Mariotti; M Rakowicz; S Szymanski; J Infante; B P C van de Warrenburg; D Timmann; R Fancellu; R Rola; C Depondt; L Schöls; E Zdzienicka; J-S Kang; S Döhlinger; B Kremer; B Melegh; A Filla; T Klockgether
Journal: Neurology Date: 2008-08-12 Impact factor: 9.910

4. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.

Authors: Roman Schniepp; Max Wuehr; Nibal Ackl; Adrian Danek; Thomas Brandt; Michael Strupp; Klaus Jahn
Journal: J Neurol Date: 2011-03-23 Impact factor: 4.849

5. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.

Authors: M Strupp; R Kalla; J Claassen; C Adrion; U Mansmann; T Klopstock; T Freilinger; H Neugebauer; R Spiegel; M Dichgans; F Lehmann-Horn; K Jurkat-Rott; T Brandt; J C Jen; K Jahn
Journal: Neurology Date: 2011-07-06 Impact factor: 9.910

6. Scale for the assessment and rating of ataxia: development of a new clinical scale.

Authors: T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu
Journal: Neurology Date: 2006-06-13 Impact factor: 9.910

7. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.

Authors: Raphael Hourez; Laurent Servais; David Orduz; David Gall; Isabelle Millard; Alban de Kerchove d'Exaerde; Guy Cheron; Harry T Orr; Massimo Pandolfo; Serge N Schiffmann
Journal: J Neurosci Date: 2011-08-17 Impact factor: 6.167

8. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.

Authors: T A Zesiewicz; P E Greenstein; K L Sullivan; L Wecker; A Miller; I Jahan; R Chen; S L Perlman
Journal: Neurology Date: 2012-02-08 Impact factor: 9.910

9. Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument.

Authors: H Jacobi; M Rakowicz; R Rola; R Fancellu; C Mariotti; P Charles; A Dürr; M Küper; D Timmann; C Linnemann; L Schöls; O Kaut; C Schaub; A Filla; L Baliko; B Melegh; J-S Kang; P Giunti; B P C van de Warrenburg; R Fimmers; T Klockgether
Journal: Cerebellum Date: 2013-06 Impact factor: 3.847

10. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Authors: Andrew D Goodman; Theodore R Brown; Lauren B Krupp; Randall T Schapiro; Steven R Schwid; Ron Cohen; Lawrence N Marinucci; Andrew R Blight
Journal: Lancet Date: 2009-02-28 Impact factor: 79.321

10 in total

9 in total

9. What is the best way to keep walking and moving around for individuals with Machado-Joseph disease? A scoping review through the lens of Aboriginal families with Machado-Joseph disease in the Top End of Australia.

Authors: Jennifer J Carr; Joyce Lalara; Gayangwa Lalara; Moira Smith; Jennifer Quaill; Alan R Clough; Anne Lowell; Ruth N Barker
Journal: BMJ Open Date: 2019-09-30 Impact factor: 2.692

9 in total

Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.

1. EuroQol--a new facility for the measurement of health-related quality of life.

Review 2. 4-aminopyridine and cerebellar gait: a retrospective case series.

3. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia.

4. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.

5. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.

6. Scale for the assessment and rating of ataxia: development of a new clinical scale.

7. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.

8. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.

9. Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument.

10. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Review 1. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.

Review 2. Spinocerebellar ataxias: prospects and challenges for therapy development.

Review 3. The physiological basis of therapies for cerebellar ataxias.

Review 4. Acquired ataxias: the clinical spectrum, diagnosis and management.

Review 5. Gait ataxia in humans: vestibular and cerebellar control of dynamic stability.

6. Consensus paper: management of degenerative cerebellar disorders.

Review 7. Update on the pharmacotherapy of cerebellar and central vestibular disorders.

Review 8. Degenerative Ataxias: challenges in clinical research.

9. What is the best way to keep walking and moving around for individuals with Machado-Joseph disease? A scoping review through the lens of Aboriginal families with Machado-Joseph disease in the Top End of Australia.